Isolating CD4+ and CD8+ T cells for improved drug efficacy and increased productivity
Sponsor
Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.
Isolating CD4+ and CD8+ T cell subsets is critical for controlling the ratio within the final drug product. It also has impacts downstream steps such as cryopreservation after isolation. Achieving younger, less differentiated T cells is important for optimizing clinical outcomes. With this in mind, Thermo Fisher Scientific is releasing a first-of-its-kind platform technology that enables isolation of CD4+ and CD8+ T cells with a key differentiator: an active release mechanism for clinical trial or commercial manufacturing.
The Gibco™ CTS™ Detachable Dynabeads™ CD4 Kit and the Gibco™ CTS™ Detachable Dynabeads™ CD8 Kit each possesses a proprietary active release mechanism that enables active release of Dynabeads from the cells at any time in the process while maintaining high cell yield. Conjugated to highly specific, single-domain VHH antibodies that target specific clusters of differentiation markers, the performance exhibits consistent and optimal isolation and purity of target T cell populations while addressing the biological variability that cell therapy manufacturers are facing.
- How the active detachment of Dynabeads from target cells at any time allows users to add flexibility and scalability to their process
- How to maintain desired cell phenotypes
- How to isolate target cells for both autologous and allogeneic processes
SPEAKERS
You might also like
T cells from beginning to end: optimizing leukopak and drug product cryopreservation
Enhancing CAR-T cell generation: optimizing non-viral engineering of resting T cells for improved cancer immunotherapy
Enhancing CAR-T efficacy for targeting lymphoma and solid tumors
Improving AAV productivity and packaging efficiency for transient and producer cell lines through plasmid engineering
